Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03466203 · ClinicalTrials.gov registry record · Phase 1
Safety Study of LLF580 in Obese Volunteers
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT03466203 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 61 participants.
The verdict
NCT03466203, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and tolerability of multiple doses of LLF580 administered subcutaneously over 3 months in obese subjects. In addition, the study will also determine early efficacy signals in various metabolic diseases associated with elevated triglycerides and/or obesity.
Interventions
- DRUG Placebo
- BIOLOGICAL LLF580
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2018-02-26 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03466203
The ClinicalTrials.gov registry entry for NCT03466203 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03466203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03466203 about?
NCT03466203 is a clinical study titled "Safety Study of LLF580 in Obese Volunteers". The purpose of the study is to evaluate the safety and tolerability of multiple doses of LLF580 administered subcutaneously over 3 months in obese subjects. In addition, the study will also determine early efficacy signals in various metabolic diseases associated with elevated triglycerides and/or o...
What is the current status of trial NCT03466203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2018-02-26. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT03466203?
The interventions under investigation include: Placebo (DRUG), LLF580 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03466203?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.